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Abstract
Barrier to autointegration factor (BAF/BANF1) is a cellular DNA-binding protein found in the nucleus and
cytoplasm. Cytoplasmic BAF binds to foreign DNA and can act as a defense against vaccinia DNA replication. To evade BAF, vaccinia expresses the B1 kinase, which phosphorylates BAF and blocks its ability to bind
DNA. Interestingly, B1 is also needed for viral intermediate gene expression via an unknown mechanism.
Therefore, we evaluated the impact of B1-BAF signaling on vaccinia transcription. Strikingly, the decrease in
vaccinia transcription caused by loss of B1 can be rescued by depletion of BAF. The repressive action of BAF
is greatest on a viral promoter, and is more modest when non-vaccinia promoters are employed, which suggests BAF acts in a gene specific manner. These studies expand our understanding of the role of the B1 kinase
during infection and provide the first evidence that BAF is a defense against viral gene expression.
Keywords: vaccinia, transcription, virus host interaction, BAF, BANF1, barrier to autointegration

Introduction

1992; Traktman et al., 1989) provided the first evidence of the essential role played by B1 during the vaccinia lifecycle (Banham
and Smith, 1992; Lin et al., 1992; Rempel and Traktman, 1992).
Subsequent genetic and biochemical analysis of B1 revealed it to
be a Ser/Thr kinase essential for viral DNA replication as well
as for optimal intermediate transcription (Banham and Smith,
1992; Kovacs et al., 2001; Lin et al., 1992), and also determined
that the lesion found in the ts2 virus abrogates B1’s kinase activity. The vaccinia B1 protein exhibits significant homology with a
family of eukaryotic kinases now referred to as vaccinia-related kinases (VRKs) (Nezu et al., 1997; Nichols and Traktman, 2004).
Importantly, Boyle and Traktman discovered that the cellular kinase VRK1, when expressed from the ts2 genome, rescued the
DNA replication defect exhibited by this virus (Boyle and Traktman, 2004). This study suggested that B1 and VRK1 both target
the same substrate needed to permit genome replication, and laid
the foundation for the identification of the barrier to autointegration factor (BAF/BANF1) as a cellular substrate of B1 and VRK1
(Wiebe and Traktman, 2007).
BAF is a highly conserved 10-kDa DNA binding protein found
in both the cytoplasm and the nucleus of many cell types, and has
been found to be important for cell survival in multiple model systems (Cai et al., 1998; Cox et al., 2011; Furukawa et al., 2003;
Lee and Craigie, 1998; Margalit et al., 2005, 2007; Puente et al.,
2011; Zheng et al., 2000). Specifically, BAF is needed for survival

Vaccinia virus is the prototypical member of the large DNA virus family Poxviridae. Like all poxviruses, vaccinia exhibits significant autonomy from the host cell and carries out its entire lifecycle in the cytoplasm. The fact that vaccinia virus is capable of
both DNA replication and transcription in this location is unique
among DNA viruses, and is achieved by a large repertoire of virusencoded proteins including multisubunit DNA and RNA polymerases and multiple accessory factors (Ahn et al., 1990; Amegadzie
et al., 1991; Challberg and Englund, 1979; Condit et al., 1991; Earl
et al., 1986; Klemperer et al., 2001; McDonald et al., 1997; Moss
et al., 1991). Functional characterization of these proteins over
the last three decades has provided broad mechanistic insights
into genome replication and transcription, which are of interest
to virology and cell biology alike. While poxviruses avoid obstacles
such as chromatin which nuclear viruses face, cytoplasmic replication means that they are also challenged by host defenses specific
to that environment. In turn, viruses employ countermeasures to
inactivate the host defenses which are the most significant threat.
Recent studies have revealed that the product of the vaccinia B1R
gene is one such countermeasure.
Analysis of temperature sensitive mutant viruses, including
the ts2 virus, which contain a point mutation within the B1 ORF
(Condit et al., 1983; Rempel et al., 1990; Rempel and Traktman,
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and differentiation of both human and mouse embryonic stem
cells (Cox et al., 2011). Additionally, attempts to deplete or knock
out BAF in Caenorhabditis elegans and Drosophila melanogaster resulted in lethal phenotypes early in embryogenesis ( Furukawa et al., 2003; Margalit et al., 2007). Recent data has also provided new insight of the importance of BAF in human disease.
Specifically, a point mutation within the BAF coding region causes
Nestor-Guillermo syndrome, a hereditary progeroid syndrome (
Puente et al., 2011).
Extensive in vitro biochemical and structural studies of BAF
have advanced our understanding of BAF’s function and regulation (Bradley et al., 2005; Haraguchi et al., 2001; Harris and Engelman, 2000; Ibrahim et al., 2011; Margalit et al., 2005; SeguraTotten et al., 2002; Segura-Totten and Wilson, 2004; Umland et
al., 2000). BAF binds double-stranded DNA independent of sequence (Lee and Craigie, 1998; Umland et al., 2000; Zheng et al.,
2000), but does not bind ssDNA, ssRNA, or dsRNA (Ibrahim et
al., 2011; Lee and Craigie, 1998). Through its ability to homodimerize, BAF can cross-bridge DNA to form higher order nucleoprotein complexes (Lee and Craigie, 1998; Zheng et al., 2000).
Phosphorylation of BAF by either the viral B1 or cellular VRK1
proteins strongly inhibits BAF’s ability to bind DNA, and regulates
BAF in both the cytoplasm and nucleus (Nichols et al., 2006).
In the nucleus, BAF interacts with LEM-domain proteins, histones, and transcriptional regulators (Dechat et al., 2004; Furukawa, 1999; Haraguchi et al., 2001; Lee et al., 2001; Margalit et
al., 2005; Montes de Oca et al., 2005, 2009; Segura-Totten et al.,
2002; Segura-Totten and Wilson, 2004; Shumaker et al., 2001).
These partners allow BAF to play an important role during nuclear
reassembly, and likely allow BAF to modulate gene expression as
well. In the cytoplasm BAF is capable of inhibiting viral DNA replication (Wiebe and Traktman, 2007). This host defense activity of
BAF depends on its DNA binding and bridging properties and is
blocked through phosphorylation in the presence of active B1 kinase (Ibrahim et al., 2011).
In this manuscript, we further explore the importance of the
B1-BAF signaling axis during poxviral infection. Specifically, we
test the hypothesis that the action of BAF explains why B1 kinase
is needed for intermediate transcription as well as DNA replication. We have determined that depletion of BAF from mouse L929
cells rescues the transcriptional defect of the ts2 B1-deficient virus.
Interestingly, the impact of BAF is greatest on the viral G8 promoter as compared with other non-vaccinia promoters examined.
Thus, our data suggests that while BAF can bind any dsDNA sequences, its ability to repress transcription is specific to the promoter BAF is acting on. Together, these data reveal a novel property of BAF as a transcriptional inhibitor and demonstrate that
vaccinia is an excellent model system for future characterization of
BAF’s function as a regulator of gene expression.
Results
The regulation of viral intermediate gene expression requires the B1 kinase independently of its role in DNA
replication
Temperature sensitive vaccinia viruses with lesions in the B1
kinase (ts2 and ts25) display a primary block at the stage of DNA
replication at nonpermissive temperature (Condit et al., 1983).
The requirement for B1 at this stage is linked to its ability to inactivate the cellular factor BAF via phosphorylation. If left unphosphorylated, BAF relocalizes to viral factories and impairs viral genome replication via its ability to bind and crossbridge DNA
(Ibrahim et al., 2011; Nichols et al., 2006; Wiebe and Traktman,
2007). Interestingly, prior to the discovery of the B1-BAF signaling axis, Kovacs et al. have shown that B1 is also required for at
least one post replicative stage in the viral life cycle. Specifically,
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using a plasmid transfection/infection approach to examine intermediate gene expression independent of DNA replication, it
was discovered that intermediate promoter activity is impaired
during infection with ts25 (Kovacs et al., 2001). However, the
mechanism through which B1 contributes to gene expression has
yet to be determined.
The goal of this present study was to further examine the role
of B1 during vaccinia intermediate gene expression and test the
hypothesis that without an active B1 kinase the cellular factor BAF
is not only able to impede DNA replication, but viral transcription
as well. To test this hypothesis, we first worked to confirm the role
of B1 in intermediate gene expression as previously reported (Kovacs et al., 2001). L929 fibroblasts were transfected with plasmids
expressing firefly luciferase under the intermediate promoters
of the G8R, A2L, I1L genes or a synthetic intermediate promoter
based on the consensus sequence described by Yang et al. (2012).
These cells were then infected with WT or ts2 viruses at an MOI
of 3 and incubated at 37 °C overnight before harvesting and measurement of luciferase activity. A temperature of 37 °C was chosen
for our studies because we found that L929 cells are highly sensitive to heat induced stress at 39.7 °C. As we found that multiple
temperature-sensitive viruses retain their ts phenotype at 37 °C
in L929 cells (see Figure 2 below), we chose to employ this temperature in our studies to minimize the impact of unknown stress
responses on the interpretation of our data. To examine viral intermediate gene expression independent of DNA replication, the
nucleoside analog cytosine arabinoside (AraC) was added during
the infection, as previous studies have shown that the expression
of vaccinia genes from a plasmid introduced into infected cells
does not require viral DNA replication (Keck et al., 1990; Vos and
Stunnenberg, 1988). As shown in Figure 1A, expression from pG8Luciferase (pG8-Luc) is inhibited in ts2-infected cells over 200fold compared to WT-infected cells. This is in line with the previous observation by Kovacs et al. that the presence of a functional
B1 kinase is necessary for the viral intermediate gene expression.
Likewise, activation of each of the A2L, I1L, and consensus intermediate promoters was significantly decreased in the ts2 infected
cells as compared to WT infected cells, demonstrating that B1 is
important for expression of intermediate genes in general. As the
pG8-Luc construct exhibited the greatest fold difference between
WT and ts2 infections, we focused on it for the remainder of our
study to allow for the greatest sensitivity in our assays.
Next, we tested whether the defect in intermediate gene expression of ts2 can be rescued by expression of B1 from the viral
TK locus of the ts2 virus. Using recombinant ts2 viruses, Boyle and
Traktman demonstrated that expression of B1 from the TK locus
of the ts2 genome rescues the DNA replication defect of this virus (Boyle and Traktman, 2004). Using the same virus, we verified that in L929 cells the expression of B1 from the ts2 virus rescued viral yield compared to ts2 alone at either low or high MOI
(Figure 1C), as was previously observed in BSC40 cells (Boyle and
Traktman, 2004). We also found that luciferase activity measured
in ts2/B1 was 50-fold higher than that found in ts2-infected cells
(Figure 1B). These results support the role of the B1 kinase during
viral intermediate gene expression, and demonstrate that expression of B1 from the ts2 genome can both rescue viral yield and enhance viral intermediate gene expression in L929 cells.
BAF affects viral intermediate gene expression in a B1
dependent manner
The above data indicate that the B1 kinase is required not only for
DNA replication, but intermediate gene expression as well. To determine whether B1 is unique in functioning at both of these stages
of the viral lifecycle, we examined whether intermediate gene expression was decreased during infection with other ts viruses displaying blocks in DNA replication. Specifically, two ts mutants
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Figure 1. The ts2 defect in intermediate transcription is observed on
multiple promoters and is rescued
by B1 expression in L929 cells. (A and
B) L929 cells were transfected with the reporter construct shown for 7 h, then infected at 37 °C with WT, ts2, or ts2/B1
as indicated (MOI=3) in the presence of
50 μM AraC. Lysates were prepared at 16 h
after infection and assayed for luciferase
activity. RLU shown is normalized to total protein measured by BCA assay. Data
were obtained from three independent experiments performed in triplicate wells.
Data from a representative experiment is
shown. Error bars represent the standard
deviation. (C) L929 cells were infected
with WT, ts2, or ts2/B1 at MOI=0.1 or
MOI=5 for 24 h at 37 °C. After lysates were
collected virus yield was determined by a
plaque titration on monolayers of BSC40
cells at 32 °C. Data were obtained from
triplicate experiments, and standard deviation is presented by the error bars. (*** indicates a p-value <0.05).

with DNA replication defects were employed: ts42 virus carries
a mutation in the viral catalytic DNA polymerase (E9) (McDonald and Traktman, 1994; Sridhar and Condit, 1983) and ts24 carries a mutation in the D5 primase/helicase protein (De Silva et al.,
2007, 2009; Evans and Traktman, 1992; Evans et al., 1995). First,
we verified that viral DNA replication was impaired at 37 °C during infection with these viruses. L929 cells were infected (MOI=3)
with WT, ts2, ts42, or ts24 and lysates were collected at 0.5 and
24 hpi for DNA quantification using quantitative PCR. As shown
in Figure 2A, while during WT infection viral DNA increased more
than 150-fold in 24 h, ts2 DNA was increased only ~3-fold compared to input and no increase in DNA was detected during ts42
and ts24 infections. These data demonstrate that in L929 cells,
37 °C is a nonpermissive temperature for each of these mutant
viruses.
Next, these viruses were used to begin our examination of the
role of BAF in intermediate gene expression. First, we transduced
L929 cells with replication-incompetent lentiviral vectors expressing either a BAF-specific or control (CTRL) shRNA. Immunoblot analysis of lysates from these cells revealed that expression of
BAF in L929-shBAF cells is decreased to 15–20% compared to
that from the untransduced L929 cells, while no impact on BAF
expression was detectable in the shCTRL cells (Figure 2B). Next,
L929-Control and -shBAF cells were transfected with pG8-Luc,
then infected with WT, ts2, ts42 or ts24 viruses (MOI=3) in the
presence of AraC for 16–20 h prior to harvest and measurement
of luciferase activity. In L929-shControl cells (Figure 2C, left), we

found that pG8-Luc reporter activity in cells infected with ts24
was identical to WT infection, and ts42 were only slightly (2.5fold) reduced. This was in clear contrast to pG8-Luc activity during ts2 infection, which was more than two orders of magnitude
lower. This result indicates that E9 and D5 do not affect intermediate gene expression and that the importance of B1 at this stage is
not common among viral DNA replication proteins.
Next, the same transfection/infection protocol was performed
in L929-shBAF cells where BAF expression is stably depleted. Interestingly, in these cells reporter gene expression was enhanced
to at least some degree regardless of the virus used (Figure 2C).
Luciferase activity in WT, ts42, and ts24 infected L929-shBAF
cells was 2–3 folds greater than that observed for each of those viruses in L929-shControl cells (Figure 2D). Strikingly however, luciferase activity in ts2 infected L929-shBAF cells was close to 40fold greater than that in L929-shControl cells (Figure 2C and D).
This specific rescue of ts2-mediated intermediate gene expression in BAF depleted cells suggests that the B1-BAF signaling axis
is important at this stage of the life cycle as well as during DNA
replication.
Depletion of B1 during WT vaccinia infection also impedes transcription in a BAF-dependent manner
To further characterize the role of B1 during intermediate gene
regulation, we examined whether siRNA-mediated depletion of
B1 would yield results similar to those obtained above with the ts2

366

Ibrahim, Wicklund, Jamin, & Wiebe

in

Virology 444 (2013)

Figure 2. The defect in intermediate
transcription is specific to ts2 and is
rescued by depletion of BAF. (A) DNA
replication assays. Total DNA was isolated
at 30 min and 24 h after infection (MOI=3)
with WT, ts2, ts42, or ts24 at 37 °C, then
quantified by qPCR. Data was obtained from
two independent experiments, PCR amplified in duplicate. Data is shown as a fold
difference compared to the WT sample at
0.5 hpi. Error bars represent standard deviation. (B) Immunoblot analysis of BAF expression in L929 cells stably depleted of BAF
using specific shRNA. Lysates from equivalent numbers of cells were collected and analyzed using antibody against BAF. The total
amounts of BAF in each lane were quantified
using a Bio-Rad Chemidoc XRS instrument.
GAPDH level was used as loading control.
(C) L929 cells stably expressing shBAF or
shControl were transfected with pG8-Luciferase for 7 h, then infected at 37 °C with WT,
ts2, ts42 or ts24 at MOI=3 in the presence of
50 μM AraC. Lysates were prepared at 16 h
after infection and assayed for luciferase activity. RLU shown is normalized to total protein measured by BCA assay. Data were obtained from three independent experiments
performed in triplicate wells. Data from a
representative experiment is shown. Error
bars represent standard deviation. (D) Data
from the luciferase expression shown in (C)
was replotted as a fold difference between the
shControl and shBAF cell lines for each virus.
(*** indicates a p-value <0.05).

virus. To establish a method for depletion B1 mRNA, L929 cells
were transfected with 100 nM of B1-specific or control siRNA for
24 h, followed by an infection with WT virus at MOI=3 at 37 C for
4 h. Two B1-specific siRNA were tested. Lysates were collected and
RNA extracted for subsequent qPCR using primers specific to the
B1 ORF. Based on RT-qPCR results (Figure 3A), the accumulation
of B1-specific transcripts was substantially reduced in siB1-pretreated cells compared non-treated cells. The decrease in B1-specific transcripts was 90% with siB1-1 and 70% with siB1-2. Due to
the greater depletion by siB1-1, we selected that siRNA for use in
subsequent studies.
To determine whether depletion of B1 results in diminished intermediate gene expression, L929 were transfected with siB1 or siControl for 12 h, then transfected with pG8-luc for 7 h before infecting with WT vaccinia in the presence of AraC. Cells transfected
only with pG8-Luc and infected with ts2+AraC were included for
comparison purposes. To simultaneously investigate the involvement of BAF in these studies, both L929-shControl and L929-shBAF cells were employed. In L929-shControl, we found that depletion of B1 leads to a substantial decrease in the activity of the
reporter gene when compared to siControl-transfected cells or
cells not treated with any siRNA (Figure 3B). Specifically, we observed an average decrease of ~40-fold in luciferase activity,
bringing the reporter activity to a level very similar to that obtained during the ts2 infection. In L929-shBAF cells, the depletion
of BAF was able to rescue the loss of intermediate gene expression
caused by siB1 treatment as well as during ts2 infection. As in Figure 2C and D, the fact that the loss of BAF specifically enhances
gene expression when B1 has been depleted further supports our

model that B1 is needed to repress the inhibitory activity of BAF.
BAF immunoprecipitates pG8-Luc DNA and depletion of
BAF rescues viral intermediate gene expression at the
transcriptional level
Although we have previously shown that BAF relocalizes to transfected dsDNA by immunofluorescence (Ibrahim et al., 2011) and
other studies have also shown BAF’s DNA-binding capability in vitro via biochemical and structural studies (Bradley et al., 2005;
Cai et al., 1998; Umland et al., 2000; Zheng et al., 2000), BAF’s
direct interaction with DNA in an intact cell has yet to be demonstrated by co-immunoprecipitation. Therefore, to validate that
BAF impairs gene expression through its direct DNA-binding activity, we performed chromatin immunoprecipitation analysis in
L929 cells stably expressing MCS empty vector (control) or FLAGBAF. Cells were transfected with 150 ng pG8-Luc plasmid for 24 h
followed by immunoprecipitation of BAF-DNA complexes. Bound
pG8-Luc DNA was analyzed by qPCR analysis using a pG8-Lucspecific primer set which flanks the G8 promoter region. In FLAGBAF-expressing cells, we observed an increase in pG8-Luc DNA
binding compared to control cells. Specifically, while the plasmid DNA harvested for the input samples was similar between the
MCS and Flag-BAF expressing cells, following immunoprecipitation the average difference in Ct was 5.3 Ct lower (Supp Figure 2)
in the Flag-BAF cells and fold enrichment ~40 fold higher than
the control cells (Figure 4A). As all previous studies of BAF have
shown that BAF binds dsDNA in a sequence independent manner we were curious as to whether BAF is preferentially binding
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with WT or ts2 virus (MOI=3) and incubated at 37 °C in the presence of AraC. At 4 hpi, lysates were collected and RNA extracted
for RT-qPCR analysis using a luciferase-specific primer/probe set.
In L929-shControl cells, the accumulation of transcripts in ts2 infected cells was reduced compared to WT infected cells (Figure
4D). This difference between ts2 and WT transcription was observed at all plasmid concentrations, but was greatest at lower
plasmid amounts. As higher amount of plasmids were used, the
difference in transcripts between WT and ts2 infection shrinks.
Next, upon examining the impact of BAF depletion on transcripts
synthesized under the viral G8 promoter, we found that ts2-mediated transcription was greater in L929-shBAF cells than in L929shControl cells. Most significantly, when using 10 ng of DNA there
was a >10-fold increase in transcript accumulation in L929-shBAF
cell as compared to ts2-infected L929-shControl cells. Together,
these data are consistent with our model that BAF can be a repressor of viral gene expression at the transcriptional level if B1 is not
present to phosphorylate it.
The impact of BAF on gene expression is promoter
dependent

Figure 3. Depletion of B1 impairs intermediate transcription
following WT virus infection, and can be rescued by BAF depletion. (A) L-929 cells were transfected with 100 nM of siRNA siControl, siB1R-1, or siB1R-2. At 24 h post transfection, cells were infected with WT virus at a MOI of 3 and total RNA harvested at 4 hpi.
Following reverse transcription, cDNA was quantified by qPCR. (B)
L929 stably expressing shBAF or shControl were transfected with
100 nM siRNA specific to B1 kinase (siB1-1) or siControl for 12 h, and
then transfected with pG8-Luciferase for 7 h, then infected at 37 °C
with WT virus at MOI=3 in the presence of 50 μM AraC. An infection
of L929 with ts2 at MOI=3 in the presence of AraC at 37 °C was also
performed. Lysates were prepared at 12 h after infection and assayed
for luciferase activity, and RLU normalized to protein level. Data were
obtained from three independent experiments performed in triplicate
wells. Data from a representative experiment is shown. Error bars represent standard deviation. (*** indicates a p-value <0.05).

the G8 promoter. Therefore, in addition to G8 promoter-specific
primers, we also utilized primers specific to the Neomycin resistance gene on the opposite site of the plasmid and the cellular
beta-actin gene. We found that the Neo region of the plasmid and
beta-actin gene were immunoprecipitated with an efficiency almost equal to the G8 promoter (Figure 4B and C). These data support a model in which BAF directly interacts with many, if not all,
regions of the plasmid construct during its impairment of gene expression. Such a model would also be consistent with previous in
vitro DNA binding data and structural studies demonstrating that
BAF binds dsDNA in a sequence independent manner.
Kovacs et al. have previously shown that B1 impacts intermediate gene expression at the level of transcription (Kovacs et al.,
2001). To confirm and extend those results, we sought to determine whether B1’s impact on transcript levels is BAF-dependent.
For these studies, L929-shControl and shBAF cells were transfected with increasing amounts of pG8-Luc plasmid, then infected

In light of the ability of BAF to bind to dsDNA in a sequence independent manner, we hypothesized that it may be capable of impacting transcription of genes other than the pG8-Luc reporter construct. To address this hypothesis, we began by asking (1) whether
the transcriptional role of BAF during gene expression is promoter
dependent and (2) whether the effect of B1 is also promoter dependent. For these studies, plasmids were employed that express firefly
luciferase under a T7, CMV or a ‘minimal’ (minP) promoter, which
contains primarily a TATA box. T7-Luc was selected to be used in
conjunction with the recombinant vaccinia virus vTF7.3, which expresses a wild-type B1 protein as well as the T7 polymerase. Thus,
transcription from the T7-Luc/vTF7.3 system will allow us to measure reporter gene expression from transcription in the cytoplasm,
but in a manner independent of the vaccinia RNA polymerase and
transcription factors. The CMV-Luc and minP-Luc constructs contain a strong and weak promoter, respectively, and are both activated by cellular factors and therefore result in nuclear transcription. As BAF is present in both the cytoplasm and nucleus, its
impact on transcription in both locations is of interest.
We began by examining the impact of the B1-BAF axis on T7mediated gene expression. L929-shBAF and shControl cells were
transfected as indicated with siB1 or siControl, then transfected
with T7-luciferase, and later infected with vTF7.3 virus at MOI=3
in the presence of AraC for an additional 16 h before harvest. As
shown in Figure 5A (left), siB1 treatment of L929-shControl cells
infected with vTF7.3 resulted in only a minor (2.5-fold) reduction
in T7-Luc reporter gene expression, contrary to what was observed
for pG8-Luc expression during WT infection (Figure 3). When the
same transfection / infection study using T7-Luc was performed
in L929-shBAF cells, transcription activity rose modestly and was
similar in all cases regardless of B1 siRNA treatment regimen.
While these data suggest the B1-BAF axis contribute somewhat to
the level of T7-driven reporter activity observed, the magnitude of
their contribution is far less than what was observed when studying the pG8-Luc reporter.
Next, we wanted to test whether the depletion of BAF can enhance the expression of a reporter gene under a promoter transcribed in the nucleus. L929-shControl and shBAF were transfected
with two different amount of CMV-Luc (immediate early promoter)
or minP-Luc plasmid for 24 h at 37 °C; then lysates were collected
and analyzed for luciferase activity. As shown in Figure 5B, at both
DNA concentrations minP promoter-mediated luciferase expression was enhanced only 2-fold in L929-shBAF cells, and the CMV
promoter-mediated luciferase expression (Figure 5C) was similar regardless of BAF level of expression. Based on the contrast be-
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Figure 4. BAF immunoprecipitates
pG8-Luc DNA in L929 cells and depletion of BAF rescues viral intermediate gene expression at the transcriptional level. (A) ChIP assays were
performed to determine the binding of
BAF to DNA. L929 cells stably expressing MCS plasmid (control) or 3xFlag-BAF
were transfected with 150 ng pG8-luciferase plasmid for 24 h. Following fixation
and sonication, BAF-DNA complex was
immunoprecipitated using anti-FLAG antibody and analyzed by quantitative PCR using primers flanking the G8 promoter (A)
or Neomycin resistance gene (B) of pG8Luc DNA or the beta-actin cellular gene
(C). Data shown is a representative from
three independent experiments, each performed in duplicate. Error bars represent
standard deviation. Data from the Raw Ct
values (shown in Figure S2) was plotted as
fold enrichment relative to MCS. (D) L929
cells stably expressing shBAF or shControl
were transfected with 10, 100, and 500 ng
of pG8-luciferase for 7 h, then infected
with 37 °C with WT or ts2 at MOI=3 in the
presence of AraC. Lysates were collected
for RNA extraction and luciferase transcripts quantified by RT-qPCR. (*** indicates a p-value <0.05).

tween these data with the T7, CMV and minP promoters and the
earlier data using the G8 promoter, it is evident that the B1-BAF
axis affects transcription in a gene specific manner. In our view, this
specificity may be due to differences in transcription factors and
polymerases in play and/or subcellular localization of the DNA in
question and is discussed in more detail below.
Discussion
Vaccinia virus possesses multiple sophisticated mechanisms to
manipulate cellular signaling pathways and subvert host defenses
(Bowie and Haga, 2005; Moss and Shisler, 2001; Perdiguero and
Esteban, 2009). Studies on vaccinia-host interactions continue to
provide novel insights into the mechanisms employed by both virus and host alike to achieve their respective goals during the course
of an infection. For example, the vaccinia B1 Ser/Thr kinase phos-

phorylates the cellular factor BAF, which leads to the potent inhibition of BAF’s ability to bind and crossbridge viral DNA (Ibrahim
et al., 2011; Wiebe and Traktman, 2007). VRK1, a cellular homolog of B1, targets BAF on the same residues as B1 (Nichols et al.,
2006). It is now known that the VRK1-BAF axis plays an important role in mitotic regulation (reviewed in Valbuena et al., 2011),
while the B1-BAF axis is needed for viral DNA replication (Ibrahim
et al., 2011; Wiebe and Traktman, 2007). Importantly, these studies revealed a novel function for BAF as an antiviral effector capable of targeting vaccinia DNA in the cytoplasm. Currently, much remains to be learned about the contributions of the B1 kinase to the
viral lifecycle and specifically whether its phosphorylation of BAF is
needed to promote more than just viral DNA replication.
The requirement of B1 for viral DNA replication, which itself is
needed for intermediate and late gene expression, is an obstacle to
the study of B1’s contribution to processes beyond DNA replication.
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Figure 5. The role of B1 kinase and BAF in viral intermediate gene expression is promoter dependent. (A) L929 stably expressing shBAF or shControl were transfected with siRNA specific to
B1 kinase (siB1-1) or siControl for 12 h, and then transfected with 1 ng
of T7-Luciferase for 7 hr, then infected with 37 °C with Wt-VTF7.3 at
MOI=3 in the presence of AraC. Lysates were prepared at 12 h after infection and assayed for luciferase activity, with RLU shown normalized
to protein level. (B and C) L929 stably expressing shBAF or shControl were transfected with the indicated amounts of minP-Luc (B) or
CMV-Luc (C). Lysates were prepared at 24 h after transfection and assayed for luciferase activity, with RLU shown normalized to protein
level. For all graphs, data were obtained from three independent experiments performed in triplicate wells. Data from a representative experiment is shown. Error bars represent standard deviation. (*** indicates a p-value <0.05).

However, as reported by Kovacs et al. (2001), by using plasmid reporters containing viral promoters to avoid the need for genome
replication, B1 was indeed found to be needed beyond DNA repli-
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cation (Kovacs et al., 2001). However, the mechanism underlying
B1’s contribution to gene expression was not fully defined. Therefore, in light of the importance of the B1-BAF axis for DNA replication, herein we examined whether B1 was acting through this
same pathway to facilitate intermediate gene expression. As expected, the B1-deficient ts2 virus was only capable of activating the
luciferase reporter gene under the G8R promoter to <1% to that of
the WT virus in L929 cells (Figure 1). The ts2 virus also exhibited
a marked reduction of expression from three other promoters in
this study, demonstrating that B1’s role in transcription likely extends to intermediate gene expression in general. A reduction in
ts2-driven reporter activation as compared to WT virus was also
observed in other cell types including CV1, U2OS, and BSC40 cells
(Figure S1A). The fact that L929 cells display the greatest sensitivity in this assay was also found by Kovacs et al., and is the reason
why they were employed for the remainder of the study. However,
it is interesting to note that all of these cell lines express similar
amounts of BAF protein (Figure S1B) indicating that either the
ts2-B1 protein or BAF exhibits cell type specific activity. Efforts to
tease out the mechanisms underlying these cell type specific differences is currently underway.
To directly test BAF’s involvement in the transcriptional downregulation seen during ts2 infection we constructed L929 cells
stably depleted of BAF and performed luciferase reporter assays
in those cells (Figure 2). Strikingly, cells with decreased levels of
BAF exhibited a 40-fold increase in ts2-mediated gene expression as compared to control L929 cells (Figure 2D). While it is interesting to note that the other viruses tested in this study (WT,
ts42, and ts24) also exhibited modestly increased reporter activation, the fact that ts2 was more dramatically affected than other
viruses demonstrates that the B1-BAF axis impacts expression of
the reporter gene. This conclusion is also supported by our complementary data that siRNA-mediated depletion of B1 from WT virus leads to a decrease in reporter activation which can be rescued
by the depletion of BAF (Figure 3B). Together, these data strongly
suggest that in the absence of the B1 kinase, BAF is capable of impairing viral gene expression.
Finally, we have made progress towards determining the mechanism underlying BAF’s impact on viral gene expression. First,
we demonstrated that multiple regions of the plasmid co-immunoprecipitates with BAF, supporting a model in which BAF binds
foreign DNA in a sequence independent manner, including interaction with the promoter region of the reporter gene. Second, we
directly tested whether BAF was affecting transcription of the reporter gene by measuring luciferase transcript accumulation during WT and ts2 infection. Using RT-qPCR, we observed that decreased transcript levels observed during ts2 infection could be
rescued by BAF depletion, indicating that BAF functions at the
level of gene transcription. The specificity of BAF’s action against
transcription was also examined using promoter-reporter constructs able to be expressed independently of the vaccinia RNA
polymerase. Interestingly, both BAF and B1 depletions had little
impact on a reporter under a T7 promoter during infection with
vTF7.3, which expresses the T7 polymerase. Similarly, BAF depletion had little if any impact on either minP or CMV driven reporter
gene expression, both of which are promoters responsive to RNA
polymerase II and cellular transcription factors. Together, these
results provide the first evidence that BAF can function as a genedependent inhibitor of transcription, which can itself be inactivated by the B1 kinase.
In regard to the mechanism of BAF’s inhibition of viral gene expression, previous studies have shown that BAF’s ability to block viral DNA replication requires its DNA binding and dimerization activity (Ibrahim et al., 2011). These properties allow BAF to bind
and crossbridge/aggregate DNA (Bradley et al., 2005; Skoko et
al., 2009; Zheng et al., 2000), and also likely allow BAF to impair
transcription in the absence of B1. Precedent for this model can be
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found in prokaryotes, where DNA crossbridging by dimeric proteins
such as H-NS is known to be a potent transcriptional silencer of foreign DNA (Lucchini et al., 2006). Interestingly, the potency of silencing due to H-NS binding is a function of the DNA binding affinity or other attributes of the transcription factors attempting to gain
access to the promoter bound by H-NS (Navarre et al., 2006, 2007),
consistent with a model in which the competition of repressor and
activator proteins determine the level of gene activation.
We posit that if BAF functions via a similar mechanism to
H-NS and is attempting to compete for DNA binding with transcriptional activators it may, in part, explain the promoter-specific repression we are observing. Following this logic, in the case
of the vaccinia promoters, the presence of BAF may be sufficient
to hinder recruitment of some of the activators found to contribute to vaccinia intermediate transcription. For example, the action
of viral proteins such as A8 and A23 (Sanz and Moss, 1999) as well
as cellular factors including G3BP/p137 (Katsafanas and Moss,
2004), TBP (Knutson et al., 2006), and Yin-Yang 1 (YY1) (Broyles
et al., 1999; Knutson et al., 2009) have been linked to intermediate transcription and their access to the promoter may be affected
by BAF. In contrast, the fact that gene expression from the T7,
minP, and CMV promoters is similar in the presence or absence
of BAF suggests that binding of the transcription factors and / or
the polymerases to those promoters may not be greatly impeded
by BAF. Additionally, as the minP and CMV promoters are transcribed in the nucleus, BAF’s activity may be regulated differently
in that environment (such as by the nuclear kinase VRK1), thus reducing BAF’s ability to repress foreign DNA. This possibility might
also explain why we have found that the beta-actin gene could be
co-immunoprecipitated with BAF (Figure 4C), while beta-actin
transcript levels remain unchanged in control or BAF-depleted
cells (data not shown). Future work to determine the relative contribution of each of these possible regulatory mechanisms will be
of great interest.
Finally, we would be remiss if we did not point out that in each
of our experiments using L929-shBAF cells, the depletion of BAF
never led to a complete recovery of the transcriptional activity lost
due to impairment of the B1 kinase. We would suggest two possible explanations for these observations. First, while BAF depletion is significant, it is still incomplete. The remaining BAF may
be capable of inhibiting intermediate gene expression. Secondly,
we posit that B1 may have substrates other than BAF that are also
needed for optimal transcription, which are mediating this difference in gene expression. In this regard one possible candidate is
the viral H5 protein, which is known to be phosphorylated by B1
and has been linked to transcriptional regulation in other studies (Black et al., 1998; Brown et al., 2000; D’Costa et al., 2008,
2010; Kovacs and Moss, 1996). Additional studies will be needed
to distinguish between these two possibilities.
In summary, these studies reveal that the B1-BAF signaling
axis impacts both DNA replication and intermediate gene expression. Our observations demonstrate for the first time that BAF
can act as a transcriptional repressor and provide the first evidence that this inhibitory activity can be regulated by phosphorylation of BAF. Although this study focuses on vaccinia transcription in the cytoplasm, the fact that a large fraction of BAF exists in
the nucleus and is targeted there by VRK1, suggest that post-translational regulation of BAF probably has implications for cellular
gene expression as well.
Materials and Methods
Cell culture, transfection and infection
All chemicals were purchased from Fisher Scientific or Sigma-Aldrich unless otherwise stated. African green monkey BSC40 kid-
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ney epithelial cells, CV1, U2OS, and mouse fibroblast L929 cells
were obtained from ATCC and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals) and penicillin-streptomycin and
incubated at 37 °C in a 5% CO2 atmosphere.
Plasmids
For transfection experiments performed in the absence of vaccinia
infection, two plasmids expressing firefly luciferase were used:
CMV-Luc expresses luciferase under the CMV immediate early
enhancer promoter (pGL4.51[luc2/CMV/Neo], Catalog# E1320),
and minP-Luc expresses luciferase under a minimal promoter
containing only a TATA box (pGL4.26[luc2/min/Hygro], Catalog# E8441). For transfection-infection experiments, pG8-luciferase expresses luciferase under the viral intermediate G8 promoter
(a generous gift from B. Moss, NIAID, Bethesda, MD), and T7-luciferase (Promega) were used.
Plasmids containing A2, I1 and Consensus Intermediate promoter sequences upstream of the firefly luciferase gene were constructed as follows. PCR was performed using pG8-Luciferase
plasmid as a template and primers designed to include sequences
previously published of I1, A2 and Consensus promoters (Baldick et al., 1992; Knutson et al., 2006; Yang et al., 2012). All three
promoters (in bold) were placed upstream of 18 bp homologous
to the 5′ end of firefly luciferase gene (in italics). Non-viral sequences including three nucleotides followed by EcoRI restriction
sites were placed upstream of the promoter sequences (in lower
case). The upstream primers are A2L-Luc (5′ccggaattcGCAACGTCTAGAAATAAAATGTTTTTATATAAAAatggaagatgccaaaaac-3′), I1L-Luc (5′-ccggaattcTTTGTATTTAAAAGTTGTTTGGTGAACTTAAATGGCagacgccaaaaacataaag-3′) and
Consensus-Luc (5′-ccggaattcTAATATATTTAAAATAAAAATTAATATTATAAAatggaagatgccaaaaac-3′). The downstream
primer, Universal-Luc-3′ (5′-caggaattcttacacggcgatcttTc-3′), is
homologous to the 3′-end of the firefly luciferase ORF, and contains an EcoRI site (lowercase) as well. PCR products amplified
using these primers were cloned into the pCRII-TOPO plasmid
(Invitrogen) using the EcoRI restriction and promoter identity
verified following DNA sequencing.
Viruses
The following viruses were used: wild-type vaccinia virus (WR
strain), the B1-deficient ts2 virus (Condit et al., 1983; Rempel et
al., 1990; Rempel and Traktman, 1992), and vTF7.3 (Fuerst et al.,
1986). Recombinant virus ts2/B1 (Boyle and Traktman, 2004) was
provided by Dr. Traktman (Medical College of Wisconsin). Viruses
ts42 (E9 mutant) and ts24 (D5 mutant) were gifts from Dr. Rich
Condit (University of Florida). Stocks of all viruses were purified
from cytoplasmic lysates of infected BSC40 cells by ultracentrifugation through 36% sucrose; and quantified by plaque assay titration on BSC40 cells.
Production of cells stably overexpressing BAF
The stable overexpression of BAF in L929 cells was performed by
using a lentivirus expressing 3XFlag-BAF (plasmids were a kind
gift from Dr. Paula Traktman (Molitor and Traktman, 2013)). Specifically, 293 T cells were transfected with pHM-3XFlag-BAF or
pHM-MCS plasmid (Mostoslavsky et al., 2006; Ory et al., 1996)
with a combination of viral packaging plasmids pVSV-G, pTat,
pREV and pGag/Pol. The next day, media was replaced with
fresh media containing 5 mM Sodium Butyrate. Eight hours later
fresh media containing 10 mM HEPES pH7.4 was added for additional 12 h. Next, media containing lentivirus was filtered through
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a 0.45 μm sterile filter, and polybrene (8 μg/ml) was added and
stored at −80 °C. For transduction, L929 cells were seeded in
35 mm dishes at 1×106 per well. The next day, medium was replaced with 1 mL of lentivirus supernatant. After 24 h, medium
was replaced with fresh media for additional 24 h. Cells were then
grown in media containing 200 μg/ml of hygromycin to select for
stable lentiviral integration.
Production of cells stably depleted of BAF
The stable depletion of BAF was performed using a lentivirus expressing a BAF-specific short hairpin RNA (shRNA) or control (scrambled) shRNA as previously described (Ibrahim et al.,
2011), with the exception that transduced cells were selected with
15 ug/ml of puromycin. To express shRNA specific to murine BAF
mRNA, the primers mBAFsense (5′-TGGCTTATGTGGTCCTTGGCTTCAAGAGAGCCAAGGACCACATAAGCCTTTTTGGAAAC-3′)
and mBAFantisense (5′-TCGAGTTTCCAAAAAGGCTTATGTGGTCCTTGGCTCTCTTGAAGCCAAGGACCACATAAGCCA-3′)
were annealed and cloned into the pLL3.7 as previously described
(Wiebe and Traktman, 2007).
Luciferase assays
Transfection-Infection experiments: L929 cells seeded at 2×105
per well of a 12-well plate were transfected using Lipofectamine
2000 (Invitrogen) with 10 ng of pG8-Luc DNA per well. The plasmid-Lipofectamine transfection complexes were prepared as follows:130 ng of pG8-luciferase and 1 μl of Lipofectamine 2000
were combined in 2.3 mL of DMEM; and 200 μl of the transfection mixture was used per well. Cells were incubated at 37 °C in a
5% CO2 atmosphere for 7 h to allow for plasmid introduction into
the cells, which were then infected with vaccinia virus at a multiplicity of infection (MOI) of 3 in media containing 50 μM AraC
and placed back in the incubator for additional 18 h. Cells were
then washed twice with phosphate-buffered saline(PBS) (10 mM
Na2HPO4−7H2O, 1 mM KH2PO4, 2 mM KCl, 140 mM NaCl [pH
7.4]), then lysed in 300 μl of 1X Reporter Lysis buffer (Promega)
by two freeze-thaw cycles. The luciferase activity was measured
using 50 μl of lysate for 100 μl of luciferase assay substrate buffer
in a Berthold multiwell Luminometer.
Transfection alone: L929 cells were seeded at 2×105 per well of a
12-well plate, and the next day they were transfected using Lipofectamine 2000 (2 μl per μg DNA; Invitrogen) with CMV-Luc or
minP-luciferase for additional 12 h. Cells were washed twice with
PBS, and then lysed with 300 μl of 1X Reporter Lysis buffer (Promega), and freeze-thaw twice. The luciferase activity was measured using 50 μl of lysate and 100 μl of luciferase assay substrate
buffer in a Berthold multiwell Luminometer. Firefly luciferase expression was normalized to relative total protein level in each lysate. Protein level in each lysate was quantified by BCA protein assay (Thermo Scientific).
Immunoblot analysis
L929 and L929 stably expressing specific shRNA were freshly collected in 300 μl of SDS sample buffer (100 mM Tris pH6.8, 2%
β-mercaptoethanol, 2% SDS, 32.5% glycerol, bromophenol blue)
supplemented with 10 units of Benzonase. Lysate volume equivalent to 105 cells were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) on a 18% gel, transferred to PVDF, and incubated with primary against BAF (Wiebe and Traktman, 2007), and
rabbit secondary antibodies. Blots were developed with chemiluminescent reagents, and quantified by a Bio-Rad Chemidoc XRS
instrument to verify that BAF expression had been depleted >85%.

B1 siRNA transfection/infection
B1-specific and control siRNAs were designed and ordered from
Dharmacon. The B1-1siRNA sense sequence is 5′–CAAUAUGCACCUAGAGAAUUU-3′ and the B1-2 siRNA sense sequence
is 5′–GCCCAAAGCUAACGGAUCAUU-3′. The siControl sense
strand sequence is 5′–CAGUCGCGUUUGCGACUGGUU-3′. L-929
cells were transfected with 100 nM of siRNA Control, siB1R-1, or
siB1R-2 using RNAimax (Life Technologies) as per manufacturer’s
protocol. 16–24 h post transfection cells were infected with WT virus at an MOI of 3 and harvested for B1R mRNA at 4 hpi. RNA was
extracted using TRIzol reagent, purified with Aurum Total RNA
mini kit (Biorad), reverse transcribed to generate cDNA (Applied
Biosystems, High Capacity cDNA Reverse Transcription Kit), and
treated with 0.5 μg/ml RNase A prior to qPCR analysis.
qPCR
qPCR performed on B1R cDNA was done using TaqMan master mix (Applied Biosystems) and 900 nM of primers B1R F
(5′-AATCAATGGGTCGTTGGACCAT-3′) and B1R R (5′-AATACATCATTTTTATCTCGGGTTTCGATTGC-3′), and 250 nM B1R
probe (5′–56-FAM/AG GTG CAG ATC TAG ATG CGG TGA TCA
/3IABkFQ-3′), specific to the vaccinia virus B1R gene. To measure viral DNA replication, DNA was extracted from the cells
with the QIAamp DNA Blood Mini Kit (Qiagen) and treated with
5 μg/ml RNase A. Viral DNA replication was quantified using
SYBR green PCR mix (Applied Biosystems) with primers specific
to the vaccinia virus HA gene at a concentration of 900 nM each
(HA F: 5′-CATCATCTGGAATTGTCACTA CTAAA-3′ and HA R:
5′-ACGGCCGACAATATAATTAATGC-3′).
ChIP Assays
L929 cells (107) stably expressing specific shRNA were transfected
with 150 ng pG8-Luc plasmid for 24 h. Cells were cross-linked
with 1% formaldehyde for 10 min at room temperature followed by
quenching with 0.75% glycine. Cell lysis was done using FA lysis
buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA
pH 8, 1% TritonX-100, 0.1% sodium deoxycholate, 0.1% SDS, and
protease inhibitor (Complete, Roche)). Lysates were sonicated
with Misonix XL-2000 Sonicator for 10×10 s at power setting 3
(output wattage 6) followed by centrifugation at 8000 g for 1 min.
A fraction (6%) of the supernatant was used as ‘input’. Clarified
lysates were then incubated at 4 °C overnight with 2 μg of antiFLAG antibody (F7425, Sigma) and an equal volume of RIPA buffer (50 mM Tris.HCl pH 8, 150 mM NaCl, 2 mM EDTA pH 8, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor). To each sample, 10 µL of Dynabeads Protein G (10003D,
Novex) were added and incubated on a rotator at 4 °C for 2 h.
Beads were washed 3 times with wash buffer (20 mM Tris–HCl
pH 8.0, 150 mM NaCl, 2 mM EDTA pH 8, 1% Triton X-100, and
0.1% SDS), and once with final wash buffer (20 mM Tris–HCl pH
8.0, 500 mM NaCl, 2 mM EDTA pH 8, 1% Triton X-100, and 0.1%
SDS). Bound complexes were eluted from the beads with elution
buffer (100 mM NaHCO3 and 1% SDS) by incubating at 30 °C for
20 min. Crosslinking was reversed by overnight incubation at 60–
65 °C in the presence of 10 µg/ml RNase A and 1 mg/ml Proteinase K. DNA was purified using Zymoclean Gel DNA Recovery Kit
(D4002, Zymo Research). Immunoprecipitated and input material
was analyzed by quantitative PCR (StepOne Plus Real Time PCR,
Applied Biosystems) using SYBR green PCR mix (Applied Biosystems) with three different primers sets as followed: G8Pro ChIP
Fwd (5′-CTTCGTGGATCCTGTAGAACG-3′) and G8Pro ChIP Rev
(5′-CCATCTTCCAGCGGATAGAATG-3′) which flank the G8 promoter of pG8-Luc DNA; Neo Fwd (5′–CTTGCTCCTGCCGAGA-
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AAGT-3′) and Neo Rev (5′–TTCGCTTGGTGGTCGAATG-3′); and
ActinB Fwd (5′–GGTCATCACTATTGGCAACG-3′) and ActinB Rev
(5′–CGTCACACTTCATGATGGAATTG-3′). Serial dilutions were
also included in each qPCR run and used to develop a standard
curve and determine the PCR efficiency of the primer sets in that
experiment set. The efficiency (E) is calculated as such: E=10(−1/
slope). Fold enrichment was calculated relative to negative control
sets as such: fold enrichment=E−(ΔCttarget – ΔCtcontrol).
Statistics
Error bars shown represent one standard deviation from the
mean. The p-values indicated were calculated using the Students
t-test.
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Appendix A. Supplementary materials

Figure S1. The defect in intermediate transcription specific to ts2 varies by cell type and does not correlate with variations in
total BAF expression. (A). Transcription assays. Cells from each of the indicated lines were plated at equal numbers and transfected with pG8Luciferase for 7 h, then infected at 37 °C with WT or ts2 (MOI=3) in the presence of 50 μm Arac. Lysates were prepared at 16 h after infection and
assayed for luciferase activity. RLU shown is normalized to total protein measured by BCA assay. Data were obtained from three independent experiments performed in triplicate wells. Data from a representative experiment is shown. Error bars represent standard deviation. (* indicates a pvalue < 0.1, *** indicates a p-value < 0.05) (B). Immunoblot analysis of BAF expression. Lysates from equivalent numbers of cells were collected
and analyzed using an antibody against BAF. The experiment was repeated twice and similar results obtained in each case.
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Figure S2. BAF immunoprecipitates Cellular and plasmid DNA in L929 cells. Raw Ct values from quantitative PCR study shown in Figure 4 using primers flanking the G8 promoter (A) or Neomycin resistance gene (B) of pG8-Luc DNA or the beta-actin cellular gene(C). Data shown
is a representative from three independent experiments, each performed in duplicate. Error bars represent standard deviation.

